Overview

Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.

Our clinical lead, BBI-001, was designed to be a safe, convenient, and effective treatment for sufferers of iron overload associated with Hereditary Hemochromatosis. By binding dietary iron to inhibit absorption, BBI-001 is designed to prevent the potentially serious consequences of unmanaged iron overload resulting from hemochromatosis, such as liver disease, heart problems, diabetes, elevated cancer risk, and significant joint pain.

Currently, there are no effective FDA-approved therapies for hemochromatosis. Phlebotomy, an alternative, can be difficult and painful for patients, and long-term adherence is low. Taken orally, BB1-001 has been proven effective in pre-clinical animal models, and is on track for clinical proof of concept in humans.

Additionally, Bond’s pipeline includes early research into the application of non-absorbed polymers to the treatment and prevention of other ion-related diseases.